The preferred and most widely studied among the selective androgen receptor modulators (SARMs), Ostarine —also referred to as MK-2866, GTX 024, or Enobosarm —arrived around the scene back again during the late 1990s as an experimental treatment for osteoporosis and certain diseases that result in insulin resistance, muscle losing, and muscle lo